Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

England Unveils £680m Innovative Medicines Fund

Bigger Than Had Been Proposed, Fund Extends Cancer Drugs Fund To Other Treatment Areas

Executive Summary

England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.

You may also be interested in...



Make It Better And Put More Money In – Industry On England’s New Innovative Medicines Fund

While they await further details on England’s new Innovative Medicines Fund, industry and other stakeholders are asking questions about how far the fund – due for launch later this year – will be adapted to fit non-cancer therapies.

England: HTA Body’s Income Hit By COVID-19

England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.

Vertex Inks New Cystic Fibrosis Deals In Europe

Reimbursement timelines in Italy and France for the treatments in question have been quicker than the average.

Topics

UsernamePublicRestriction

Register

PS144675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel